BGI Genomic's $250 Million Shenzhen IPO Scheduled for July
publication date: Jun 23, 2017
BGI Genomics, the contract sequencing/diagnostic divisions of China's BGI, is edging closer to an IPO. The company now expects to raise $250 million on Shenzhen's Chi-Next Exchange sometime in July, following all-but-final approvals from China's Securities Regulatory Commission. Known as a world leader in basic science sequencing, BGI now generates 55% of its income from clinical genomic tests, especially its NIFTY prenatal test for hereditary illnesses such as Down's syndrome. The business is very profitable: BGI's IPO prospectus puts gross profit margin for reproductive services at 76%. More details....
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.